ANTI-TOXOPLASMA IGM TEST LABELING CHANGES MUST BE MADE BY JULY, FDA TELLS MANUFACTURERS; RESULTS OF FDA/CDC TEST SENSITIVITY STUDY DUE BY MID-1997
This article was originally published in The Gray Sheet
Executive Summary
Labeling changes to clarify performance limitations of anti-Toxoplasmosis gondii IgM antibody tests "should be in effect within six months, or the next printing of [test] labeling, whichever occurs first," FDA says in a letter sent to manufacturers the week of Jan. 13.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.